1. Home
  2. KALA vs BIOR Comparison

KALA vs BIOR Comparison

Compare KALA & BIOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KALA
  • BIOR
  • Stock Information
  • Founded
  • KALA 2009
  • BIOR 2010
  • Country
  • KALA United States
  • BIOR United States
  • Employees
  • KALA N/A
  • BIOR N/A
  • Industry
  • KALA Biotechnology: Pharmaceutical Preparations
  • BIOR Biotechnology: Pharmaceutical Preparations
  • Sector
  • KALA Health Care
  • BIOR Health Care
  • Exchange
  • KALA Nasdaq
  • BIOR Nasdaq
  • Market Cap
  • KALA 27.7M
  • BIOR 25.4M
  • IPO Year
  • KALA 2017
  • BIOR 2020
  • Fundamental
  • Price
  • KALA $6.14
  • BIOR $0.65
  • Analyst Decision
  • KALA Strong Buy
  • BIOR Strong Buy
  • Analyst Count
  • KALA 2
  • BIOR 1
  • Target Price
  • KALA $16.50
  • BIOR $15.00
  • AVG Volume (30 Days)
  • KALA 7.9K
  • BIOR 140.3K
  • Earning Date
  • KALA 08-06-2024
  • BIOR 08-12-2024
  • Dividend Yield
  • KALA N/A
  • BIOR N/A
  • EPS Growth
  • KALA N/A
  • BIOR N/A
  • EPS
  • KALA N/A
  • BIOR N/A
  • Revenue
  • KALA N/A
  • BIOR $860,000.00
  • Revenue This Year
  • KALA N/A
  • BIOR $32,550.00
  • Revenue Next Year
  • KALA N/A
  • BIOR $95.48
  • P/E Ratio
  • KALA N/A
  • BIOR N/A
  • Revenue Growth
  • KALA N/A
  • BIOR 777.55
  • 52 Week Low
  • KALA $4.21
  • BIOR $0.48
  • 52 Week High
  • KALA $11.21
  • BIOR $2.71
  • Technical
  • Relative Strength Index (RSI)
  • KALA 46.39
  • BIOR 53.79
  • Support Level
  • KALA $5.73
  • BIOR $0.63
  • Resistance Level
  • KALA $6.08
  • BIOR $0.71
  • Average True Range (ATR)
  • KALA 0.18
  • BIOR 0.03
  • MACD
  • KALA 0.03
  • BIOR -0.00
  • Stochastic Oscillator
  • KALA 57.14
  • BIOR 60.75

About KALA KALA BIO Inc.

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

About BIOR Biora Therapeutics Inc.

Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology.

Share on Social Networks: